Research and exploration of combined application of selumetinib and osimertinib in the treatment of lung cancer

Lung cancer is a malignant tumor with relatively high morbidity and mortality worldwide, and research on its treatment has always been a hot topic in the medical community. In recent years, the epidermal growth factor receptor (EGFR) inhibitor osimertinib has performed well in the treatment of lung cancer. However, as treatment progresses, some patients will develop resistance to osimertinib. In order to overcome this problem, researchers have begun to explore the combination of osimertinib and other drugs. Among them, the combination with selumetinib has attracted much attention.

Selumetinib, a mitogen-activated protein kinase (MEK) 1/2 inhibitor, was found to overcome acquired resistance to osimertinib in preclinical models. This discovery provides new ideas for lung cancer treatment. In order to verify the effectiveness of this idea, a number of studies have been conducted around the world, the most representative of which are the TATTON study and the FLAURA2 study.

In the TATTON study, the therapeutic effect of osimertinib combined with selumetinib on EGFR mutated non-small cell lung cancer (NSCLC) was evaluated. The study results show that this combination therapy has anti-cancer activity against EGFRmutated NSCLC, especially in the treatment of METnegative, advanced EGFRm NSCLC patients. Although some adverse effects occurred in the study, overall the safety and tolerability of this combination therapy were as expected.

On the other hand, the FLAURA2 study explored the application of osimertinib combined with chemotherapy in the first-line treatment of EGFR advanced NSCLC patients with sensitive mutations. The results of the study show that compared with osimertinib monotherapy, combination chemotherapy can significantly extend the progression-free survival (PFS) of patients, and the safety is controllable. This finding is for EGFRsensitive mutation late stageNSCLCPatients offered new treatment strategies.